au Den del af patienterne, som ophørte med behandling på grund af bivirkninger i løbet af den dobbeltblindede, kontrollerede del af forsøg I- IX, CLASSIC I, GAIN og CHARM udgjorde 5. 7% for patienter, der fik Trudexa, og 5. 3% for kontrolbehandlede patienter. re Bivirkninger, hvor kausaliteten er mindst muligt relateret til adalimumab for forsøgne I- IX, CLASSIC I, GAIN og CHARM både klinisk og laboratoriemæssigt, er opført efter organklassesystem og ge
r ge The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I− IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking Trudexa and 5.3% for control treated patients. lon Adverse events at least possibly causally-related to adalimumab for Studies I− IX, CLASSIC I, GAIN and CHARM, both clinical and laboratory, are displayed by system organ class and frequency (very common ≥ 1/ 10; common≥ 1/ 100 < 1/ 10; uncommon≥ 1/ 1000 to ≤ 1/ 100) and rare < 1/ 1000 in Table no